Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Bio-Rad Laboratories, with a focus on how actual results compare to estimates, which could significantly impact stock price [1][2]. Earnings Expectations - Bio-Rad is expected to report quarterly earnings of $2.30 per share, reflecting a year-over-year increase of 14.4%. Revenues are projected to be $651.42 million, up 0.3% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial estimates during this period [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate matches the Zacks Consensus Estimate for Bio-Rad, resulting in an Earnings ESP of 0%. The stock currently holds a Zacks Rank of 4, complicating predictions for an earnings beat [12]. Historical Performance - In the last reported quarter, Bio-Rad exceeded expectations by posting earnings of $2.61 per share against an expected $1.93, achieving a surprise of 35.23%. Over the last four quarters, the company has beaten consensus EPS estimates three times [13][14]. Conclusion - While Bio-Rad does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release